Jazz Pharmaceuticals
JAZZ
550 hedge funds and large institutions have $7.45B invested in Jazz Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 99 funds opening new positions, 221 increasing their positions, 155 reducing their positions, and 52 closing their positions.
168% more call options, than puts
Call options by funds: $66.4M | Put options by funds: $24.7M
90% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 52
43% more repeat investments, than reductions
Existing positions increased: 221 | Existing positions reduced: 155
8% more funds holding
Funds holding: 508 → 550 (+42)
2% more capital invested
Capital invested by funds: $7.28B → $7.45B (+$170M)
0.99% more ownership
Funds ownership: 97.8% → 98.79% (+0.99%)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
+$64.2M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$52.5M |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$51.1M |
| 4 |
PL
Perpetual Ltd
Sydney, New South Wales,
Australia
|
+$46.7M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$38.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$179M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$142M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$120M |
| 4 |
Millennium Management
New York
|
-$76.9M |
| 5 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$59.7M |
JAZZ Hedge Fund Activity: Q1 2025 in Review
550 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2025, worth a combined $7.45B — up 2.3% from $7.28B a quarter earlier.
Buyers outnumbered sellers: 99 funds opened new JAZZ positions and 52 closed out — a net gain of 47 holders — while 221 added to existing stakes and 155 trimmed.
The largest buyer was Holocene Advisors, opening a new position worth an estimated $64.2M. The largest seller was Pacer Advisors, cutting an estimated $179M.
- 550 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2025, up from 508 in Q4 2024.
- Funds reported $7.45B of Jazz Pharmaceuticals stock for Q1 2025, up 2.3% quarter-over-quarter.
- 99 funds opened new Jazz Pharmaceuticals positions in Q1 2025 and 52 closed out, a net change of +47 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2025 was Holocene Advisors, an estimated $64.2M added.
- The largest Jazz Pharmaceuticals seller in Q1 2025 was Pacer Advisors, an estimated $179M sold.
Based on aggregated 13F filings for Q1 2025.